Skip to main content
. 2014 Aug 6;18(8):1519–1539. doi: 10.1111/jcmm.12278

Fig. 2.

Fig. 2

Forest plot showing analysis of median pooled PFS or TTP and 90% accuracy intervals during treatment with single-agent erlotinib, single-agent gefitinib or chemotherapy in all lines of treatment in patients with EGFR mutation-positive NSCLC. PFS: progression-free survival; TTP: time to progression; EGFR: epidermal growth factor receptor; NSCLC: non-small-cell lung cancer.